GoodRx, a resource for healthcare savings and information, is working with Sanofi, a company that specializes in diabetes care, to offer people living with diabetes access to Lantus (insulin glargine ...

In March of this year the three largest insulin manufacturers announced a dramatic reduction in the price of many commonly prescribed insulins and a monthly out-of-pocket (OOP) cap of $35 that went ...

Overview: Insulin glargine is a long-acting insulin used to lower blood sugar levels in people with diabetes. It helps get sugar into your cells, so your body can use it for energy. The most common ...

A pharmacist holds a box of the drug Lantus SoloStar, made by Sanofi Pharmaceutical, at a pharmacy in Provo (Reuters) - GoodRx said on Thursday it has collaborated with Sanofi to offer the drugmaker's ...

Two long-acting insulin analogs have been developed for use as "basal" components of insulin treatment regimens: glargine and detemir. (Insulin glargine has US Food and Drug Administration [FDA] ...

BDCDA alerts trade fraternity about theft of Lantus SoloStar of Sanofi India: Nandita Vijayasimha, Bengaluru Thursday, March 5, 2026, 08:00 Hrs [IST] The Bangalore District Chemis ...

The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) on December 16 announced that the U.S. Food and Drug Administration (FDA) granted approval for Basaglar ...

Gov. Gavin Newsom announced on Thursday that the first state-made insulin would be available at the start of 2026.California’s CalRx® Insulin Glargine in 3mL pen form will be $55 per five-pack. That's ...

COPENHAGEN, Jan 8 (Reuters) - Denmark's Novo Nordisk (NOVOb.CO), opens new tab said on Monday its COMBINE 3 phase 3a drug trial had shown that a weekly injection of IcoSema was superior in controlling ...